Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$313M Buy
2,349,443
+849,443
+57% +$96.1M 7.32% 3
2026
Q1
$167M Sell
1,500,000
-400,000
-21% -$47.3M 4.67% 3
2025
Q4
$256M Buy
1,900,000
+900,000
+90% +$98.2M 8.71% 1
2025
Q3
$84.9M Buy
+1,000,000
New +$61.3M 3.83% 4

Other funds holding ABVX

Vestal Point Capital's ABVX Position: Q2 2026 in Review

Vestal Point Capital increased its Abivax (ABVX) stake by 57% in Q2 2026, buying an estimated $96.1M and bringing the position to 2,349,443 shares worth $313M. The position accounts for 7.32% of the portfolio, ranked #3.

Vestal Point Capital first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Vestal Point Capital held 2,349,443 shares of Abivax worth $313M as of Q2 2026.
  • Vestal Point Capital bought 849,443 Abivax shares in Q2 2026, an estimated $96.1M.
  • Abivax made up 7.32% of Vestal Point Capital's portfolio in Q2 2026, its #3 holding.
  • Vestal Point Capital first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.